Ipsen

  • Français
Symbol Last Change
IPN.PA 26.00 € (-1.52 % )
powered by Euronext©
  • The Group
    • Profile & Key figures
      • Message from the Chairman
      • Group history
    • R & D
      • R & D Homepage
      • Neurology
      • Endocrinology
      • Uro-Oncology
    • Medicines
    • Governance
      • Board of directors
      • Board committees
      • Leadership
      • Compensation of corporate officers
    • Business Development & Alliance Management
    • Ipsen worldwide
  • Targeted diseases
    • Neurology
    • Endocrinology
    • Uro-oncology
    • Primary care
  • Commitments
    • Vision, mission and action principles
    • Environment, health and safety
    • Ethics and compliance
    • Support to Patient Organizations
    • Corporate Citizenship
  • Fondation IPSEN
    • La Fondation Ipsen at a glance
    • Colloques, prizes, publications
      • Neurosciences
      • Alzheimer’s disease
      • Endocrinology
      • Cancer science
      • Longevity
      • Vascular
    • Partnerships
      • Salk Institute - Nature
      • Cell Press - DMM Global Foundation
      • Nature Publishing Group

Press releases

  • 25 April 2013 - Paris (France)
    Ipsen expects Increlex® supply interruption due to supplier manufacturing issues
    application/pdf icon
    Download
  • 25 April 2013 - Paris (France)
    Active Biotech and Ipsen update the analysis plan for the 10TASQ10 trial evaluating tasquinimod in the treatment of...
    application/pdf icon
    Download
  • 25 April 2013 - Paris (France)
    Ipsen’s first quarter 2013 sales
    application/pdf icon
    Download

All press releases

News

25 April 2013
About Increlex®
Lire la suite

All news

  • Go to

    PrintPrint
    • Press room
    • Investor relations
    • Careers

    YOUR SERVICES

    • Publications
    • Email alert
    • Follow Ipsen on Facebook Twitter Linked in
© Ipsen 2010
  • Legal disclaimer
  • Site Map
  • Contact
  • Email alert
  • RSS
  • Ipsen worldwide
  • IPSEN related sites

Ipsen Group website.